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Aim: Early post- acute myocardial infarction pericardial effusions are the 
major pericardial complications. We aimed to analyse the frequency, treat-
ments, characteristics and prognostic signi¿ cance of pericardial effusion (PE) 
following acute myocardial infarction.
Methods: From the French regional RICO survey database, all the patients 
hospitalized between January 1st 2001 and December 31st 2009 for an acute 
myocardial infarction from the 6 private or public center of Côte d’Or with 
echocardiographic examination were included in the study. The diagnosis of 
PE was made by echocardiography, which was performed within 48H after 
hospital admission. Data from patients with and without PE were compared at 
baseline and at follow- up.
Results: During the inclusion period, 8680 patients were included in the 
study, of whom 135 (1.5%) were diagnosed with PE. Patients with and without 
PE had similar risk factors, including age and sex ratio and time delays to 
admission. Interestingly, dyslipidemia and history of MI was less frequent in 
PE group (respectively 31 vs 45%, p=0.002 and 4 vs 13%, p=0.004). Plasma 
CRP levels on admission were markedly higher in PE patients (21 vs 6mg/l, 
p<0.001). Prior chronic treatments were less frequent in PE group, in parti-
cular for aspirin (11 vs 19%, p=0.027), ACE inhibitor (10 vs 18%, p=0.014) 
and statin (15 vs 23%, p=0.054). Acute treatments were similar, except for 
BetaBlocker that were more used in patients without PE. Patients with PE 
were more likely to suffer from STEMI (76 vs 48%, p<0.01), and altered 
LVEF. Hospital complications such as death, or heart failure (12 vs 7%, 
p=0.016, 47 vs 28%, p=0.001), and mechanical complications including atrial 
¿ brillation, wall rupture, apical thrombus and mitral regurgitation (respecti-
vely, 20 vs 9%, p<0.001, 7 vs 0.5%, p<0.01, 8 vs 0.7%, p<0.01, and 8 vs 3%, 
p=0.03) were more frequent in PE group. 
Conclusions: Our large study showed that, although PE is uncommon in 
the contemporary era of acute MI, this complication is still associated with 
worse short term prognosis, characterized by high rate of mechanical compli-
cations. Our works also suggest a preventive effect of some CV drugs against 
the development of PE following acute MI.
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Le tramadol, un antalgique d’action centrale issu de synthèse chimique, est 
introduit dans l’arsenal thérapeutique depuis 1977.Vue ses différentes présen-
tations galéniques et son action antalgique assez rapide et ef¿ cace (palier II 
des antalgiques de l’OMS), son utilisation clinique est assez répandue tant par 
voie orale, que parentérale ainsi que par voie locorégionale. L’ampleur que 
prend l’usage du tramadol après le retrait du dextroprpoxyphéne du marché, 
n’est pas assez anodine. Dans notre service de cardiologie, nous avons constaté 
sur une période de 5mois des perturbations d’INR chez une population ayant 
reçu du tramadol en IVL. Cette population etant un groupe de 6 patients d’âge 
moyen 46+- 19,5 ans dont 4 de sexe féminin et 2 de sexe masculin traité par 
l’acénocoumarol. L’arrêt du tramadol par la suite restaure l’INR à sa valeur 
cible entre 2 à 3 ou 3 à 4,5 selon le contexte clinique de l’anticoagulation. 
cette restauration n’est pas immédiate mais l’INR se restaure au bout d’une 
durée moyenne de 5jours. Dans notre étude, on a refuté l’hypothèse avançant 
que le tramadol interfére avec l’analyse biologique de TQ et INR vue l’ab-
sence de signes d’hémorragie. Ceci en réalisant des témoins contenant le sang 
des patients non anticoagulés et recevant du tramadol. L’hypothèse la plus pro-
bable de cette intéraction est d’ordre pharmacocinétique, impliquant l’étape 
de biotransformation et plus précisement celle qui se déroule au niveau des 
microsomes hépatiques via les cytochromes P450.
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Background: While proper platelet function is a vital component of 
hemostasis, their inappropriate activation contributes to thrombotic disorders 
and can lead to myocardial infarction. It is well known that calcium and actin 
cytoskeleton are crucial to ensure platelet functions through many intracellular 
signalling. In epithelial cells, Ca(2+)/calmodulin- dependent protein kinase 
kinase beta (CaMKKbeta) controls actin cytoskeleton organization through 
AMP- activated protein kinase (AMPK), extending the role of AMPK beyond 
metabolism.
Objectives: In this study, we asked whether activation of the AMPK 
pathway by thrombin could play a role in platelet aggregation.
Results: In human puri¿ ed platelets, thrombin leads to a transient AMPK 
activation and to phosphorylation of acetyl coA carboxylase which is comple-
tely prevented by a preincubation of platelets with STO- 609, a selective inhi-
bitor of CaMKKbetaҠҏ 
In addition, STO- 609 abrogated thrombin- induced aggregation and conco-
mitantly affected activation of the a2bbeta3 ¿ brinogen receptor. STO- 609 
also induced a default in secretion of alpha- granules content, reÀ ected by the 
decreased detection of CD62P at platelet surface.
The phosphorylation of myosin light chains (MLC), known to play a crucial 
role during platelet contraction, was also signi¿ cantly decreased in presence 
of STO- 609. Eventually, the implication of AMPK in the control of platelet 
aggregation and in MLC phosphorylation was demonstrated in platelets from 
alpha1 - AMPK knockout mice treated ex vivo with thrombin.
Conclusion: The role of AMPK extends beyond metabolic homeostasis. 
Regulation of cytoskeletal targets, namely MLC, could confer to AMPK a 
crucial role in the control of platelet aggregation.
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The metabolic syndrome is associated with modi¿ cations in the arterial 
wall and in blood coagulation. Our purpose was to characterize the blood coa-
gulation phenotype with age in Zucker rats which have some of the same 
disorders that de¿ ne the metabolic syndrome in humans.
We characterized this phenotype in 25 and 80 week old rats. Our study is 
measured endothelial dysfunction markers and pro- or anticoagulant factors. 
We adapted a thrombinography technique which follows thrombin activity 
after stimulation by tissue factor. An in vivo hypercoagulability state has 
been found by the measurement of F1+2 fragments of prothrombin and the 
thrombin/antithrombin (TAT) complex.
In vitro reactivity of the blood coagulation system was estimated by the 
endogenous thrombin potential which was higher in 25 week old obese rats 
than in lean rats of the same age (428±29 nM.min versus 328±27nM.min) and 
still higher at 80 weeks (422±30 versus 306±11nM.min). This result was cor-
roborated by F1+2 test in vivo at 25 weeks. Obese rat hypercoagulability did 
not depend on platelets because it was investigated in platelet free plasma. 
Hypercoagulability was associated with endothelial dysfunction shown by a 
high plasma concentration of von Willebrand factor. The ¿ brinogen increase 
could explain such growth in thrombin generation in vitro. There was no 
increase in thrombin generation in vitro with ageing whatever the strain consi-
dered despite an increase in TAT complexes.
To conclude, we have shown that thrombin generation increased in vitro, 
independent of platelet activation, from 25 weeks old obese Zucker rats. We 
suggest an implication of pro- inÀ ammatory factors in this hypercoagulablility 
state. In vitro and in vivo coagulability test reactivity changes during ageing 
must be investigated with the inÀ uence of metabolic factors, as well as inÀ am-
matory and cellular activation.
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Objectives: To determine whether glycemic control impact the extent of 
platelet inhibition by thienopryidines as assessed by vasodilator- stimulated 
phosphoprotein À ow cytometry (VASP- FCT) in patients with diabetes mel-
litus (DM) undergoing percutaneous coronary intervention during acute coro-
nary syndrome. 
Background: Whilst the proportion of high on treatment residual platelet 
reactivity is higher in DM, the respective contribution of glycemic control 
and other factors associated with DM such as overweight and inÀ ammation in 
this impaired platelet inhibition by thienopyridines are unfully characterized. 
Methods: In this study, the extent of the P2Y12 ADP receptor pathway inhi-
bition was evaluated by the VASP- FCT. Platelet activation is expressed as the 
platelet reactivity index (PRI). PRI was measured at least 6 hours after clopi-
dogrel loading dose. LR was de¿ ned as a PRI of >61%, a threshold previously 
identi¿ ed as the optimal cut- off value to predict cardiac death following PCI. 
Results: 160 consecutive ACS DM patients (STEMI 33.8%, NSTEMI 
49.4%) were enrolled. LR was evidenced in 50% of DM patients. No rela-
tionship could be evidenced between HbA1c, glycemia and PRI values. In 
univariate analysis, LR was associated with age, male sex, overweight, and 
WBC. In multivariate analysis, WBC >10,000 and weight >80kg were the 
sole independent predictors of LR to clopidogrel (respectively HR 3.02 [1.36- 
6.68], p=0.006 and 2.47 [1.14- 5.35]; p=0.021). 
Conclusions: In ACS DM patients undergoing PCI, the extent of P2Y12 
inhibition by clopidogrel is not related to the glycemic control but to ove-
rweight and to the inÀ ammatory status as assessed by the WBC.
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Background: In the modern era of primary percutaneous coronary interven-
tion (PPCI) and antiplatelet therapy combining aspirin, clopidogrel +/-GP IIB/
IIIa inhibitor, few is known on incidence, predictors and long term outcome 
of reinfarction (reMI) after an ST- elevation myocardial infarction (STEMI).
Methods: We analyzed 322 patients who reported STEMI <12h and who 
underwent PPCI in our institution between April 2003 and July 2009 and for 
whom 2 years follow- up was available. No exclusion criterion was considered. 
ReMI using universal de¿ nition was systematically collected.
Results: Incidence of reMI (n=31) was relatively high, 5% at 30 days, 8% 
at 1 year and 9.6% at 2 years including 4.7% of stent thrombosis at 30 days 
and 6.5% at 1 and 2 years. Over the time, incidence of both reMI and stent 
thrombosis dramatically decreased from 2003/2004 to 2008/2009, respectively 
from 15.5 to 5% for reMI and 13.1 to 2% for stent thrombosis. In patients pre-
senting with reMI, there were 80% of new STEMI and almost 70% of de¿ -
nite or probable stent thrombosis, which always presented as new STEMI. 
Mortality at 2 years in patients alive at discharged was 28.6% in the reMI 
group vs. 7.3% in non- reMI group (p<0.001). Finally, the strongest predictor 
of either reMI or stent thrombosis was the alteration of the left ventricular 
ejection fraction at hospital discharge.
Conclusions: Although decreasing over the time, the incidence of reMI after 
STEMI remains noteworthy and associated with poor outcome at 2 years in 
real life. ReMI commonly presents as a new STEMI due to stent thrombosis.
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Background: Studies in other countries have shown a signi¿ cant reduction 
in hospitalizations for acute coronary syndrome (ACS) after smoking bans 
Aims:  Assess trends in hospitalizations for ACS after implementation of 
a smoking ban in France (February 2007, except for bars, hotels, restaurants, 
discos and casinos for which the implementation occurred only in January 
2008)
Methods: Analysis of admissions for ACS from 2003 to 2009 from the 
national PMSI database
Results: There was a steady decrease in hospitalizations for ACS 
throughout the period with a signi¿ cant linear trend (p <0.01) but this trend 
was not more pronounced after February 2007 and January 2008. For each 
period after 1 February 2007, the relative risk, studied by Poisson regression, 
was not signi¿ cant 
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Comments: This non signi¿ cant effect of a smoking ban could be explained 
by:
• a regular and signi¿ cant decrease of the ACS largely prior to the smoking 
ban
• the implementation in two phases of the smoking ban, which decreases 
the chances to reveal an effect
• and mainly, a lesser exposure to passive smoking of the population prior 
to this smoking ban, due to the implementation of the Evin’s law in 1992. This 
third hypothesis is consistent with:
- the analysis of passive smoking in non- smoking patients hospitalized for 
ACS: 23.7% for the Scottish survey (Pell JP et al, NEJM 2008) vs. 3.3% for 
the EVINCOR- USIC study 
- French data showing a prior and signi¿ cant decrease of passive smoking 
in the general population (Tilloy E et al. Eur J Cardiovasc Prev Rehabil 2010)
- the results from other studies showing a reduced effect or no effect of 
smoking bans in case of pre- existing restrictions on smoking (Herman PM et 
al. Am J Public Health.2010) 
Conclusion: This study did not reveal a speci¿ c effect of the most recent 
French smoking ban on ACS. This result could be explained primarily by a lower 
level of passive smoking exposure of the population before this smoking ban.
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ADMA and SDMA (symmetrical stereoisomer) are novel modulating 
pathways for cardiovascular oxidative stress and endothelial dysfunction. HDL 
has been found to exert important endothelial atheroprotective effects and low 
levels of HDL cholesterol are associated with an increased risk of acute myo-
cardial infarction (MI). In patients with acute MI, we investigated the rela-
tionship between HDL and dimethylarginines serum levels. 
Blood samples from 373 consecutive patients hospitalized <24 hours after 
acute MI were taken on admission. Blood lipids were determined using auto-
mated enzymatic methods. Serum levels of ADMA, SDMA and L- arginine (L- 
arg) were determined using high- performance liquid chromatography. Patients 
with low HDL (<0.40mg/dL for men and <0.50mg/dL for women) were com-
pared with patients with higher HDL.
Patients with low HDL were younger (64 vs. 68 y, p=0.001), more fre-
quently female (28 vs. 19%, p=0.005), with higher body mass index (27±5 
vs. 26±4kg/m²) and abdominal obesity (53 vs. 44%, p=0.036). Low HDL 
was also associated with higher triglycerides (1.69±0.81 vs. 1.19±0.81mg/dL, 
p<0.001), CRP (4.6(2.9- 11.9) vs. 5.8(3.0- 17.5) mg/L, p=0.047) but lower total 
cholesterol (1.91±0.49 vs. 2.00±0.43mg/dL, p=0.028). LDL was similar for 
the 2 groups. ADMA levels were markedly higher (+30%) in low HDL group 
(0.92±0.42 vs. 0.70±0.37mole/L, p<0.001), while SDMA and L- arg levels 
were similar for the 2 groups. ADMA, but not SDMA, was strongly correlated 
with HDL (r=- 0.329, p<0.001 and r=0.063, p=0.22). By multivariate analysis, 
ADMA level was the most powerful factor associated with low HDL levels 
(OR(95%CI): 7.43(3.44- 16.08)), even when adjusted for confounding.
Our large prospective study showed for the ¿ rst time in MI patients that 
reduced HDL was associated with increased levels of ADMA, but not of 
SDMA levels, suggesting that increased CV risk associated with low HDL- 
cholesterol could be mediated through ADMA- related effects.
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Background: Myocardial infarction with ST segment elevation (STEMI) is 
a medical emergency requiring speci¿ c management aiming to achieve reper-
fusion as early as possible.
Aims: We aimed to evaluate the temporal trends between 2002 and 2010 
in STEMI management and time delays in an eastern region of France (Cote 
d’Or).
Methods: All consecutive patients admitted for a ¿ rst STEMI in the RICO 
survey (Observatoire des Infarctus de Côte d’Or) from 1st January 2002 to 
31st December 2010 have been included. We analysed trends in pre- hospital 
and hospital management times and reperfusion.
Results: 4114 STEMI patients were included over the study period. Mean 
age and GRACE risk score increased from 2002 to 2010 (64 to 67 y, p=0.001 
and 152 to 155 p=0.049). At symptom onset, there was an increase in the rate 
of patients who called the emergency number (dial 15) and a decrease in the 
rate of call to GP as ¿ rst medical contact (from 24.8 to 39.4% and from 57.1 
to 34.2%, respectively). However, prehospital times including patient time 
(from onset of symptoms to call for medical seeking) remained stable over 
time. There was a signi¿ cant difference in time to ¿ rst medical contact accor-
ding to age, with patients aged less than 50 years getting help on average 
40 to 100 minutes earlier than patients aged over 50 years. (p=0.019). The 
average time from ¿ rst medical contact to reperfusion decreased signi¿ cantly 
from 339 minutes in 2002 to 239 minutes in 2010 (p=0.009). Over the study 
period, there was an inversion in the distribution of reperfusion strategies, 
with a decrease in ¿ brinolysis and an increase in primary PCI (from 35% 
to 27% and from 23.1 to 36.7%, respectively). The rate of patients without 
acute reperfusion dropped from 41.9 to 36.3% (p<0.001). We found a marked 
improvement in time to reperfusion including ¿ brinolysis and door to balloon 
time (from 150 to 120min and from 70 to 45min, respectively). 
Conclusion: Between 2002 and 2010, despite marked improvements in 
management including reperfusion strategies, there is still a room for impro-
vement in order to achieve earlier reperfusion in STEMI patients.
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